aleniglipron vs Semaglutide (Ozempic)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline
aleniglipron
Developed by Structure Therapeutics
NCT05762471 · Phase 1/2 · completed
The study randomized 142 participants to GSBR-1290 or placebo with participants, care providers, and investigators masked. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. Its registered primary outcome on ClinicalTrials.gov is "Incidence, severity and relationship of AE/SAE, vital signs, laboratory measures and ECG to assess safety and tolerability of multiple oral doses of GSBR-1290 in HOV and T2DM". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
Registered primary endpoint is safety/tolerability; the weight results are the phase 2a obesity cohort's efficacy readout from the sponsor's SEC-filed topline release, not yet peer reviewed.
Next expected readout: September 2028 · NCT07654374 (registry estimate)
Reported efficacy
Incidence, severity and relationship of AE/SAE, vital signs, laboratory measures and ECG to assess safety and tolerability of multiple oral doses of GSBR-1290 in HOV and T2DM (42 days): Placebo-adjusted mean weight decrease 6.2% (p<0.0001) at 12 weeks with GSBR-1290 120mg (n=37) vs placebo (n=27); 67% achieved >=6% and 33% >= 10% weight loss vs 0% for placebo (met)
Result source: NCT05762471
Semaglutide (Ozempic)
Marketed by Novo Nordisk
NCT01720446 · Phase 3 · completed
This was a large randomized, double-blind, placebo-controlled trial with 1,648 participants receiving semaglutide and 1,649 receiving placebo. The hard clinical primary endpoint, first major adverse cardiovascular event, occurred in 6.6% versus 8.9% of participants; the prespecified non-inferiority comparison was met (hazard ratio 0.74, 95% CI 0.58–0.95, p<0.0001), and a post hoc superiority analysis was statistically significant (p=0.0167).
Next expected readout: November 2026 · NCT06954090 (registry estimate)
Reported efficacy
Number of Participants From Time of Randomization to First Occurrence of Onset of Persistent ≥50% Reduction in eGFR(CKD-EPI); Onset of Persistent eGFR(CKD-EPI) <15mL/Min/1.73m^2; Initiation of Chronic Renal Replacement Therapy; Renal Death; CV Death (From Week 0 up to Week 234): Primary composite kidney outcome (kidney failure, sustained >=50% eGFR decline, or death from kidney/cardiovascular causes): 331 first events (semaglutide) vs 410 first events (placebo); HR 0.76 (95% CI 0.66-0.88), P=0.0003. (met)
Result source: NCT03819153
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | aleniglipron | Semaglutide (Ozempic) |
|---|---|---|
| HbA1c, change | —Trial running · NCT07654374 | -1.6% vs 0%−1.6 vs placeboNCT0205489735 other results
|
| Body weight, change (kg) | —Trial running · NCT07654374 | -4.9 vs -0.6−4.3 vs placeboNCT0172044632 other results
|
| HbA1c below 7% | —Trial running · NCT07654374 | 72.3% vs 24.8%+47.5 vs placeboNCT0205489710 other results
|
| Fasting plasma glucose, change | —Trial running · NCT07654374 | -2.1 vs -0.9−1.2 vs placeboNCT0172044624 other results
|
| 3-point MACE (% with event) | —Trial running · NCT07654374 | 6.6% vs 8.9%−2.3 vs placeboNCT017204461 other result
|
HbA1c, change
- aleniglipron
- —Trial running · NCT07654374
- Semaglutide (Ozempic)
- -1.6% vs 0%−1.6 vs placeboNCT02054897
35 other results
- -1.9% vs -0.1% NCT02305381
- -1.6% vs -0.2% NCT03086330
- -1.5% vs 0% NCT02054897
- -1.4% vs -0.1% NCT02305381
- -1.5% vs -0.9% NCT01885208
- -1.6% vs -0.6% NCT01930188
- -1.8% vs -1.1% NCT02648204
- -1.6% vs -0.8% NCT02128932
- -1.7% vs -1.1% NCT03191396
- -1.3% vs -0.6% NCT01930188
- -1.5% vs -1.1% NCT02648204
- -1.2% vs -0.8% NCT02128932
- -1.5% vs -1.2% NCT03689374
- -1.4% vs -0.7% NCT05514535
- -1.4% vs -0.4% NCT01720446
- -1.1% vs -0.4% NCT01720446
- -0.9% vs -0.0% NCT03819153
- -1.8% vs -0.3% NCT05649137
- -0.8% vs 0.2% NCT04560998
- -2.0% vs -0.7% NCT02207374
- -2.2% vs -0.7% NCT02254291
- -1.7% vs -0.7% NCT02207374
- -1.9% vs -0.7% NCT02254291
- -1.4% vs -0.7% NCT05514535
- -1.9% vs -1.1% NCT05486065
- -1.1% vs -0.4% NCT05144984
- -2.1% vs -1.1% NCT05486065
- -1.8% vs -1.1% NCT05486065
- -2.3% vs -0.4% NCT05144984
- -2.2% vs -0.4% NCT05144984
- -2.2% vs -0.4% NCT05144984
- -2.3% vs -0.4% NCT05144984
- -0.5% vs 0% NCT04538352
- -1.4% vs -1.0% NCT03596450
- -1.5% vs -1.1% NCT03596450
Body weight, change (kg)
- aleniglipron
- —Trial running · NCT07654374
- Semaglutide (Ozempic)
- -4.9 vs -0.6−4.3 vs placeboNCT01720446
32 other results
- -3.6 vs -0.6 NCT01720446
- -5.5 vs -1.4 NCT03819153
- -4.7 vs -0.9 NCT02054897
- -6.4 vs -1.4 NCT02305381
- -4.7 vs -1 NCT03086330
- -3.7 vs -0.9 NCT02054897
- -3.7 vs -1.4 NCT02305381
- -14.9 vs -4.6 NCT05649137
- -5.2 vs -1.2 NCT04560998
- -5.6 vs -1.9 NCT01885208
- -6.1 vs -1.9 NCT01930188
- -6.5 vs -2.3 NCT02648204
- -5.2 vs 1.1 NCT02128932
- -5.8 vs -2 NCT03191396
- -4.3 vs -1.9 NCT01930188
- -3.5 vs 1.1 NCT02128932
- -4.2 vs 2.9 NCT03689374
- -4.2 vs -0.4 NCT03061214
- -4.6 vs -2.3 NCT02648204
- -3 vs -0.4 NCT03061214
- -5.7 vs -4.3 NCT03136484
- -8.0 vs 0.4 NCT05514535
- -8.9 vs -2.3 NCT05486065
- -4.7 vs -2.6 NCT05144984
- -13.1 vs -2.3 NCT05486065
- -10.1 vs -2.3 NCT05486065
- -8.9 vs -2.6 NCT05144984
- -12 vs -2.6 NCT05144984
- -10 vs -2.6 NCT05144984
- -12 vs -2.6 NCT05144984
- -5 vs -3.1 NCT03596450
- -8.6 vs 1.4 NCT04538352
HbA1c below 7%
- aleniglipron
- —Trial running · NCT07654374
- Semaglutide (Ozempic)
- 72.3% vs 24.8%+47.5 vs placeboNCT02054897
10 other results
- 78.6% vs 10.5% NCT02305381
- 82.5% vs 20.5% NCT03086330
- 74.2% vs 24.8% NCT02054897
- 60.6% vs 10.5% NCT02305381
- 78.7% vs 52.2% NCT02648204
- 84% vs 49.6% NCT03061214
- 80.4% vs 45.9% NCT03191396
- 68.4% vs 52.2% NCT02648204
- 74.5% vs 49.6% NCT03061214
- 76.1% vs 50.8% NCT03136484
Fasting plasma glucose, change
- aleniglipron
- —Trial running · NCT07654374
- Semaglutide (Ozempic)
- -2.1 vs -0.9−1.2 vs placeboNCT01720446
24 other results
- -1.8 vs -0.9 NCT01720446
- -2.4 vs -0.6 NCT02054897
- -2.4 vs -0.5 NCT02305381
- -2.3 vs 0.1 NCT03086330
- -2.4 vs -0.6 NCT02054897
- -1.6 vs -0.5 NCT02305381
- -3.3 vs -1.1 NCT05649137
- -2.8 vs -2 NCT01885208
- -2.6 vs -1.1 NCT01930188
- -2.8 vs -1.9 NCT02648204
- -2.7 vs -2.1 NCT02128932
- -2.6 vs -1 NCT03061214
- -2.6 vs -1.5 NCT03191396
- -2.1 vs -1.1 NCT01930188
- -2.2 vs -1.9 NCT02648204
- -2.0 vs -2.1 NCT02128932
- -1.3 vs -0.8 NCT03689374
- -2.2 vs -1 NCT03061214
- -2.5 vs -2 NCT03136484
- -1.4 vs -0.1 NCT05144984
- -3.9 vs -0.1 NCT05144984
- -3.4 vs -0.1 NCT05144984
- -3.8 vs -0.1 NCT05144984
- -3.8 vs -0.1 NCT05144984
3-point MACE (% with event)
- aleniglipron
- —Trial running · NCT07654374
- Semaglutide (Ozempic)
- 6.6% vs 8.9%−2.3 vs placeboNCT01720446
1 other result
- 12% vs 14.4% NCT03819153
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. aleniglipron: 0 of 4 rows · Semaglutide (Ozempic): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Semaglutide (Ozempic) |
|---|---|
| Dropout rate | 1.3%1.0 mga NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3 show 47 more results1.7%0.5 mg NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3 —1.0 mg NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 7.9%1.0 mg NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 2.4% NCT03819153 · Phase 3 5.4%1.0 mg weekly NCT02054897 · Phase 3 7.8%0.5 mg weekly NCT02054897 · Phase 3 5.1%1.0 mg weekly NCT01930188 · Phase 3 · combination 5.4%0.5 mg weekly NCT01930188 · Phase 3 · combination 5.3%1.0 mg/week NCT02128932 · Phase 3 7.5%0.5 mg/week NCT02128932 · Phase 3 3.8%2.0 mg weekly NCT03989232 · Phase 3 2.1%1.0 mg weekly NCT03989232 · Phase 3 3.8%1.0 mg weekly NCT02305381 · Phase 3 3.8%0.5 mg weekly NCT02305381 · Phase 3 0% NCT04126603 · Phase 4 · registry result, not featured evidence 0% NCT05786521 · Phase 4 · registry result, not featured evidence 10.6% NCT05533632 · Phase 4 · registry result, not featured evidence 0%once weekly NCT04538352 · Phase 4 · registry result, not featured evidence · combination 28.1% NCT03596450 · Phase 4 · registry result, not featured evidence 36.5%Insulin Icodec + Semaglutide NCT05813912 · Phase 3 · registry result, not featured evidence · combination —Insulin Icodec + Semaglutide: Trea NCT05813912 · Phase 3 · registry result, not featured evidence · combination —INSULIN GLARGINE (REDUCED) + SEMAG NCT05514535 · Phase 3 · registry result, not featured evidence · combination 1.7%Insuline Glargine U100 (Reduced) + NCT05514535 · Phase 3 · registry result, not featured evidence · combination 3.9%7.2 mg NCT05649137 · Phase 3 · registry result, not featured evidence 18.3%1.0 mg NCT04865770 · Phase 3 · registry result, not featured evidence 7.6% NCT04560998 · Phase 3 · registry result, not featured evidence 1.5% NCT05259033 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 — NCT03689374 · Phase 3 · registry result, not featured evidence 9.7%1.0 mg weekly NCT03061214 · Phase 3 · registry result, not featured evidence 8.7%0.5 mg weekly NCT03061214 · Phase 3 · registry result, not featured evidence 6.9% NCT03136484 · Phase 3 · registry result, not featured evidence · combination 1%1.0 mg NCT03191396 · Phase 3 · registry result, not featured evidence 2.6%1.0 mg weekly NCT03086330 · Phase 3 · registry result, not featured evidence 7%1.0 mg NCT02648204 · Phase 3 · registry result, not featured evidence 7.3%0.5 mg NCT02648204 · Phase 3 · registry result, not featured evidence 4.1%1.0 mg NCT02207374 · Phase 3 · registry result, not featured evidence 2.5%0.5 mg NCT02207374 · Phase 3 · registry result, not featured evidence 2.9%1.0 mg NCT02254291 · Phase 3 · registry result, not featured evidence 0%0.5 mg NCT02254291 · Phase 3 · registry result, not featured evidence 8.2%2.0 mg NCT05486065 · Phase 2 · registry result, not featured evidence 11.3%16.0 mg NCT05486065 · Phase 2 · registry result, not featured evidence 12.9%8.0 mg NCT05486065 · Phase 2 · registry result, not featured evidence 3.4%21.6 mg NCT05144984 · Phase 2 · registry result, not featured evidence 3.9%2.4 mg + 12.0 mg NCT05144984 · Phase 2 · registry result, not featured evidence · combination 3.9%2.4 mg + 2.4 mg NCT05144984 · Phase 2 · registry result, not featured evidence · combination 3.9%2.4 mg + 21.6 mg NCT05144984 · Phase 2 · registry result, not featured evidence · combination 2.7%2.4 mg + 7.2 mg NCT05144984 · Phase 2 · registry result, not featured evidence · combination |
| Discontinued due to AEs | —1.0 mga NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3 show 47 more results—0.5 mg NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3 —1.0 mg NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 —1.0 mg NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 — NCT03819153 · Phase 3 —1.0 mg weekly NCT02054897 · Phase 3 —0.5 mg weekly NCT02054897 · Phase 3 —1.0 mg weekly NCT01930188 · Phase 3 · combination —0.5 mg weekly NCT01930188 · Phase 3 · combination —1.0 mg/week NCT02128932 · Phase 3 —0.5 mg/week NCT02128932 · Phase 3 —2.0 mg weekly NCT03989232 · Phase 3 —1.0 mg weekly NCT03989232 · Phase 3 —1.0 mg weekly NCT02305381 · Phase 3 —0.5 mg weekly NCT02305381 · Phase 3 — NCT04126603 · Phase 4 · registry result, not featured evidence — NCT05786521 · Phase 4 · registry result, not featured evidence 3.8% NCT05533632 · Phase 4 · registry result, not featured evidence —once weekly NCT04538352 · Phase 4 · registry result, not featured evidence · combination 2.2% NCT03596450 · Phase 4 · registry result, not featured evidence —Insulin Icodec + Semaglutide NCT05813912 · Phase 3 · registry result, not featured evidence · combination —Insulin Icodec + Semaglutide: Trea NCT05813912 · Phase 3 · registry result, not featured evidence · combination —INSULIN GLARGINE (REDUCED) + SEMAG NCT05514535 · Phase 3 · registry result, not featured evidence · combination —Insuline Glargine U100 (Reduced) + NCT05514535 · Phase 3 · registry result, not featured evidence · combination —7.2 mg NCT05649137 · Phase 3 · registry result, not featured evidence —1.0 mg NCT04865770 · Phase 3 · registry result, not featured evidence — NCT04560998 · Phase 3 · registry result, not featured evidence — NCT05259033 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 — NCT03689374 · Phase 3 · registry result, not featured evidence —1.0 mg weekly NCT03061214 · Phase 3 · registry result, not featured evidence —0.5 mg weekly NCT03061214 · Phase 3 · registry result, not featured evidence — NCT03136484 · Phase 3 · registry result, not featured evidence · combination —1.0 mg NCT03191396 · Phase 3 · registry result, not featured evidence —1.0 mg weekly NCT03086330 · Phase 3 · registry result, not featured evidence 0%1.0 mg NCT02648204 · Phase 3 · registry result, not featured evidence 0%0.5 mg NCT02648204 · Phase 3 · registry result, not featured evidence —1.0 mg NCT02207374 · Phase 3 · registry result, not featured evidence —0.5 mg NCT02207374 · Phase 3 · registry result, not featured evidence —1.0 mg NCT02254291 · Phase 3 · registry result, not featured evidence —0.5 mg NCT02254291 · Phase 3 · registry result, not featured evidence —2.0 mg NCT05486065 · Phase 2 · registry result, not featured evidence —16.0 mg NCT05486065 · Phase 2 · registry result, not featured evidence —8.0 mg NCT05486065 · Phase 2 · registry result, not featured evidence —21.6 mg NCT05144984 · Phase 2 · registry result, not featured evidence —2.4 mg + 12.0 mg NCT05144984 · Phase 2 · registry result, not featured evidence · combination —2.4 mg + 2.4 mg NCT05144984 · Phase 2 · registry result, not featured evidence · combination —2.4 mg + 21.6 mg NCT05144984 · Phase 2 · registry result, not featured evidence · combination —2.4 mg + 7.2 mg NCT05144984 · Phase 2 · registry result, not featured evidence · combination |
| Serious AEs | 33.6%1.0 mga NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3 show 47 more results35%0.5 mg NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3 9.4%1.0 mg NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 —1.0 mg NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 49.6% NCT03819153 · Phase 3 5.4%1.0 mg weekly NCT02054897 · Phase 3 5.5%0.5 mg weekly NCT02054897 · Phase 3 7.3%1.0 mg weekly NCT01930188 · Phase 3 · combination 7.3%0.5 mg weekly NCT01930188 · Phase 3 · combination 4.7%1.0 mg/week NCT02128932 · Phase 3 6.1%0.5 mg/week NCT02128932 · Phase 3 4.4%2.0 mg weekly NCT03989232 · Phase 3 5.2%1.0 mg weekly NCT03989232 · Phase 3 9.2%1.0 mg weekly NCT02305381 · Phase 3 6.1%0.5 mg weekly NCT02305381 · Phase 3 0% NCT04126603 · Phase 4 · registry result, not featured evidence 0% NCT05786521 · Phase 4 · registry result, not featured evidence 1% NCT05533632 · Phase 4 · registry result, not featured evidence 22.5%once weekly NCT04538352 · Phase 4 · registry result, not featured evidence · combination 6% NCT03596450 · Phase 4 · registry result, not featured evidence —Insulin Icodec + Semaglutide NCT05813912 · Phase 3 · registry result, not featured evidence · combination 3.2%Insulin Icodec + Semaglutide: Trea NCT05813912 · Phase 3 · registry result, not featured evidence · combination 5.9%INSULIN GLARGINE (REDUCED) + SEMAG NCT05514535 · Phase 3 · registry result, not featured evidence · combination —Insuline Glargine U100 (Reduced) + NCT05514535 · Phase 3 · registry result, not featured evidence · combination 9.8%7.2 mg NCT05649137 · Phase 3 · registry result, not featured evidence 19.7%1.0 mg NCT04865770 · Phase 3 · registry result, not featured evidence 18.7% NCT04560998 · Phase 3 · registry result, not featured evidence 6.2% NCT05259033 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 7.4% NCT03689374 · Phase 3 · registry result, not featured evidence 6.6%1.0 mg weekly NCT03061214 · Phase 3 · registry result, not featured evidence 6.3%0.5 mg weekly NCT03061214 · Phase 3 · registry result, not featured evidence 4.6% NCT03136484 · Phase 3 · registry result, not featured evidence · combination 5.9%1.0 mg NCT03191396 · Phase 3 · registry result, not featured evidence 4.7%1.0 mg weekly NCT03086330 · Phase 3 · registry result, not featured evidence 7.7%1.0 mg NCT02648204 · Phase 3 · registry result, not featured evidence 5.6%0.5 mg NCT02648204 · Phase 3 · registry result, not featured evidence 5%1.0 mg NCT02207374 · Phase 3 · registry result, not featured evidence 7.9%0.5 mg NCT02207374 · Phase 3 · registry result, not featured evidence 2%1.0 mg NCT02254291 · Phase 3 · registry result, not featured evidence 5.8%0.5 mg NCT02254291 · Phase 3 · registry result, not featured evidence 6.7%2.0 mg NCT05486065 · Phase 2 · registry result, not featured evidence 1.6%16.0 mg NCT05486065 · Phase 2 · registry result, not featured evidence 3.3%8.0 mg NCT05486065 · Phase 2 · registry result, not featured evidence 3.4%21.6 mg NCT05144984 · Phase 2 · registry result, not featured evidence 2.6%2.4 mg + 12.0 mg NCT05144984 · Phase 2 · registry result, not featured evidence · combination 7.8%2.4 mg + 2.4 mg NCT05144984 · Phase 2 · registry result, not featured evidence · combination 6.5%2.4 mg + 21.6 mg NCT05144984 · Phase 2 · registry result, not featured evidence · combination 4.1%2.4 mg + 7.2 mg NCT05144984 · Phase 2 · registry result, not featured evidence · combination |
| Most frequent reported AEs | 1.0 mga nausea 21.8% (placebo 7.5%) diarrhoea 18% (placebo 11.8%) vomiting 14.8% (placebo 5.1%) NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3 show 42 more results0.5 mg diarrhoea 17.9% (placebo 11.8%) nausea 17.3% (placebo 7.5%) lipase increased 11.4% (placebo 8%) NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3 1.0 mg nausea 22.3% diarrhoea 11.4% lipase increased 10.1% NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 1.0 mg weekly nausea 23.8% (placebo 7.8%) diarrhoea 10.8% (placebo 2.3%) headache 6.9% (placebo 6.2%) NCT02054897 · Phase 3 0.5 mg weekly nausea 20.3% (placebo 7.8%) diarrhoea 12.5% (placebo 2.3%) headache 11.7% (placebo 6.2%) NCT02054897 · Phase 3 1.0 mg weekly nausea 16.8% (placebo 4.5%) vomiting 11.5% (placebo 3%) diarrhoea 6.9% (placebo 1.5%) NCT02305381 · Phase 3 0.5 mg weekly nausea 11.4% (placebo 4.5%) lipase increased 9.1% (placebo 3%) nasopharyngitis 8.3% (placebo 10.5%) NCT02305381 · Phase 3 abdominal pain 60% NCT05786521 · Phase 4 · registry result, not featured evidence once weekly pain 17.5% upper respiratory infection 0% NCT04538352 · Phase 4 · registry result, not featured evidence · combination nausea 19.1% vomiting 8.5% upper respiratory tract infection 7.4% NCT05813912 · Phase 3 · registry result, not featured evidence · combination nausea 18.4% diarrhoea 13.5% vomiting 9.7% NCT05514535 · Phase 3 · registry result, not featured evidence · combination 7.2 mg nausea 29% (placebo 11.8%) diarrhoea 18.2% (placebo 8.8%) vomiting 16.6% (placebo 2.9%) NCT05649137 · Phase 3 · registry result, not featured evidence 1.0 mg covid-19 5.6% (placebo 0%) decreased appetite 5.6% (placebo 0%) diabetic retinopathy 5.6% (placebo 5.7%) NCT04865770 · Phase 3 · registry result, not featured evidence covid-19 7.6% (placebo 5.3%) nausea 5.6% (placebo 0.8%) NCT04560998 · Phase 3 · registry result, not featured evidence covid-19 14.4% diarrhoea 12.1% nausea 11.5% NCT05259033 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 nausea 14.8% diarrhoea 7.4% nasopharyngitis 6.5% NCT03689374 · Phase 3 · registry result, not featured evidence 1.0 mg weekly diarrhoea 16.9% nausea 13.4% upper respiratory tract infection 13.1% NCT03061214 · Phase 3 · registry result, not featured evidence 0.5 mg weekly diarrhoea 20.2% upper respiratory tract infection 9.8% lipase increased 7.7% NCT03061214 · Phase 3 · registry result, not featured evidence nausea 22.7% diarrhoea 15.1% vomiting 12.8% NCT03136484 · Phase 3 · registry result, not featured evidence · combination 1.0 mg nausea 21.5% diarrhoea 15.6% decreased appetite 10.4% NCT03191396 · Phase 3 · registry result, not featured evidence 1.0 mg weekly nausea 19.3% (placebo 3.3%) diarrhoea 11.3% (placebo 6%) vomiting 9.3% (placebo 2%) NCT03086330 · Phase 3 · registry result, not featured evidence 1.0 mg nausea 21% diarrhoea 13.7% vomiting 10.3% NCT02648204 · Phase 3 · registry result, not featured evidence 0.5 mg nausea 22.3% diarrhoea 14.3% vomiting 10% NCT02648204 · Phase 3 · registry result, not featured evidence 1.0 mg nasopharyngitis 31.1% nausea 19.1% diarrhoea 15.8% NCT02207374 · Phase 3 · registry result, not featured evidence 0.5 mg nasopharyngitis 33.9% constipation 18.4% nausea 12.1% NCT02207374 · Phase 3 · registry result, not featured evidence 1.0 mg nasopharyngitis 17.6% nausea 12.7% constipation 11.8% NCT02254291 · Phase 3 · registry result, not featured evidence 0.5 mg nasopharyngitis 16.5% constipation 14.6% nausea 10.7% NCT02254291 · Phase 3 · registry result, not featured evidence 2.0 mg nausea 21.7% (placebo 15.3%) vomiting 18.3% (placebo 6.8%) diarrhoea 15% (placebo 11.9%) NCT05486065 · Phase 2 · registry result, not featured evidence 16.0 mg nausea 37.1% (placebo 15.3%) vomiting 25.8% (placebo 6.8%) diarrhoea 21% (placebo 11.9%) NCT05486065 · Phase 2 · registry result, not featured evidence 8.0 mg nausea 41.7% (placebo 15.3%) diarrhoea 33.3% (placebo 11.9%) vomiting 23.3% (placebo 6.8%) NCT05486065 · Phase 2 · registry result, not featured evidence 21.6 mg injection site erythema 10.2% (placebo 0%) injection site reaction 10.2% (placebo 0%) diarrhoea 8.5% (placebo 11.5%) NCT05144984 · Phase 2 · registry result, not featured evidence 2.4 mg + 12.0 mg diarrhoea 14.3% (placebo 11.5%) constipation 9.1% (placebo 1.6%) covid-19 7.8% (placebo 13.1%) NCT05144984 · Phase 2 · registry result, not featured evidence · combination 2.4 mg + 2.4 mg nausea 19.5% (placebo 1.6%) diarrhoea 14.3% (placebo 11.5%) covid-19 7.8% (placebo 13.1%) NCT05144984 · Phase 2 · registry result, not featured evidence · combination 2.4 mg + 21.6 mg diarrhoea 13% (placebo 11.5%) nausea 13% (placebo 1.6%) covid-19 11.7% (placebo 13.1%) NCT05144984 · Phase 2 · registry result, not featured evidence · combination 2.4 mg + 7.2 mg diarrhoea 21.6% (placebo 11.5%) lipase increased 12.2% (placebo 3.3%) nausea 12.2% (placebo 1.6%) NCT05144984 · Phase 2 · registry result, not featured evidence · combination |
Notes
- aPopulation comparability has not been reviewed for 43 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Semaglutide (Ozempic)
show 1 more result
show 35 more results
show 24 more results
show 32 more results
+ 119 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: aleniglipron's landscape · Semaglutide (Ozempic)'s landscape